![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: GRB2 |
Gene summary for GRB2 |
![]() |
Gene information | Species | Human | Gene symbol | GRB2 | Gene ID | 2885 |
Gene name | growth factor receptor bound protein 2 | |
Gene Alias | ASH | |
Cytomap | 17q25.1 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | B0LPF3 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2885 | GRB2 | GSM4909293 | Human | Breast | IDC | 1.90e-16 | 4.87e-01 | 0.1581 |
2885 | GRB2 | GSM4909296 | Human | Breast | IDC | 8.66e-06 | -1.28e-01 | 0.1524 |
2885 | GRB2 | GSM4909297 | Human | Breast | IDC | 4.33e-05 | 7.64e-02 | 0.1517 |
2885 | GRB2 | GSM4909309 | Human | Breast | IDC | 4.16e-03 | -7.94e-02 | 0.0483 |
2885 | GRB2 | GSM4909311 | Human | Breast | IDC | 8.04e-13 | -1.27e-01 | 0.1534 |
2885 | GRB2 | GSM4909312 | Human | Breast | IDC | 5.03e-03 | 3.02e-02 | 0.1552 |
2885 | GRB2 | GSM4909313 | Human | Breast | IDC | 2.86e-03 | -4.66e-02 | 0.0391 |
2885 | GRB2 | GSM4909319 | Human | Breast | IDC | 4.37e-23 | -2.56e-02 | 0.1563 |
2885 | GRB2 | GSM4909321 | Human | Breast | IDC | 4.93e-03 | -1.04e-02 | 0.1559 |
2885 | GRB2 | NCCBC14 | Human | Breast | DCIS | 1.35e-10 | 3.74e-01 | 0.2021 |
2885 | GRB2 | NCCBC2 | Human | Breast | DCIS | 6.75e-07 | 9.97e-02 | 0.1554 |
2885 | GRB2 | NCCBC5 | Human | Breast | DCIS | 2.97e-10 | 2.18e-01 | 0.2046 |
2885 | GRB2 | P1 | Human | Breast | IDC | 1.76e-06 | -4.22e-02 | 0.1527 |
2885 | GRB2 | DCIS2 | Human | Breast | DCIS | 2.28e-39 | 1.38e-01 | 0.0085 |
2885 | GRB2 | LZE2T | Human | Esophagus | ESCC | 1.21e-03 | 5.66e-01 | 0.082 |
2885 | GRB2 | LZE4T | Human | Esophagus | ESCC | 1.30e-25 | 7.82e-01 | 0.0811 |
2885 | GRB2 | LZE7T | Human | Esophagus | ESCC | 2.26e-07 | 6.22e-01 | 0.0667 |
2885 | GRB2 | LZE8T | Human | Esophagus | ESCC | 8.60e-04 | 5.33e-02 | 0.067 |
2885 | GRB2 | LZE20T | Human | Esophagus | ESCC | 4.74e-02 | 2.88e-01 | 0.0662 |
2885 | GRB2 | LZE22D1 | Human | Esophagus | HGIN | 1.24e-03 | 7.96e-02 | 0.0595 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007121425 | Skin | cSCC | cellular response to abiotic stimulus | 135/4864 | 331/18723 | 2.26e-09 | 8.11e-08 | 135 |
GO:010400425 | Skin | cSCC | cellular response to environmental stimulus | 135/4864 | 331/18723 | 2.26e-09 | 8.11e-08 | 135 |
GO:000726523 | Skin | cSCC | Ras protein signal transduction | 132/4864 | 337/18723 | 6.17e-08 | 1.57e-06 | 132 |
GO:190290329 | Skin | cSCC | regulation of supramolecular fiber organization | 145/4864 | 383/18723 | 1.67e-07 | 3.71e-06 | 145 |
GO:0031334112 | Skin | cSCC | positive regulation of protein-containing complex assembly | 97/4864 | 237/18723 | 3.22e-07 | 6.51e-06 | 97 |
GO:007147925 | Skin | cSCC | cellular response to ionizing radiation | 39/4864 | 72/18723 | 3.30e-07 | 6.62e-06 | 39 |
GO:000931424 | Skin | cSCC | response to radiation | 166/4864 | 456/18723 | 4.37e-07 | 8.41e-06 | 166 |
GO:0051258112 | Skin | cSCC | protein polymerization | 114/4864 | 297/18723 | 1.55e-06 | 2.62e-05 | 114 |
GO:000756827 | Skin | cSCC | aging | 127/4864 | 339/18723 | 1.80e-06 | 3.02e-05 | 127 |
GO:004343426 | Skin | cSCC | response to peptide hormone | 150/4864 | 414/18723 | 2.11e-06 | 3.43e-05 | 150 |
GO:003812724 | Skin | cSCC | ERBB signaling pathway | 55/4864 | 121/18723 | 2.77e-06 | 4.38e-05 | 55 |
GO:001021225 | Skin | cSCC | response to ionizing radiation | 64/4864 | 148/18723 | 3.64e-06 | 5.50e-05 | 64 |
GO:000701529 | Skin | cSCC | actin filament organization | 156/4864 | 442/18723 | 7.37e-06 | 1.02e-04 | 156 |
GO:003297029 | Skin | cSCC | regulation of actin filament-based process | 142/4864 | 397/18723 | 8.50e-06 | 1.13e-04 | 142 |
GO:1902905112 | Skin | cSCC | positive regulation of supramolecular fiber organization | 83/4864 | 209/18723 | 8.87e-06 | 1.17e-04 | 83 |
GO:000189223 | Skin | cSCC | embryonic placenta development | 39/4864 | 82/18723 | 2.08e-05 | 2.43e-04 | 39 |
GO:006145825 | Skin | cSCC | reproductive system development | 149/4864 | 427/18723 | 2.30e-05 | 2.65e-04 | 149 |
GO:004860824 | Skin | cSCC | reproductive structure development | 148/4864 | 424/18723 | 2.40e-05 | 2.74e-04 | 148 |
GO:000717323 | Skin | cSCC | epidermal growth factor receptor signaling pathway | 48/4864 | 108/18723 | 2.42e-05 | 2.76e-04 | 48 |
GO:0032271112 | Skin | cSCC | regulation of protein polymerization | 89/4864 | 233/18723 | 2.57e-05 | 2.91e-04 | 89 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0471424 | Breast | IDC | Thermogenesis | 75/867 | 232/8465 | 8.41e-21 | 3.04e-19 | 2.27e-19 | 75 |
hsa0520824 | Breast | IDC | Chemical carcinogenesis - reactive oxygen species | 71/867 | 223/8465 | 2.55e-19 | 7.53e-18 | 5.63e-18 | 71 |
hsa0491523 | Breast | IDC | Estrogen signaling pathway | 35/867 | 138/8465 | 2.55e-07 | 5.18e-06 | 3.88e-06 | 35 |
hsa0520523 | Breast | IDC | Proteoglycans in cancer | 42/867 | 205/8465 | 7.69e-06 | 9.99e-05 | 7.48e-05 | 42 |
hsa0516324 | Breast | IDC | Human cytomegalovirus infection | 39/867 | 225/8465 | 6.66e-04 | 5.41e-03 | 4.05e-03 | 39 |
hsa0520322 | Breast | IDC | Viral carcinogenesis | 34/867 | 204/8465 | 2.82e-03 | 1.86e-02 | 1.39e-02 | 34 |
hsa052147 | Breast | IDC | Glioma | 16/867 | 75/8465 | 3.30e-03 | 2.10e-02 | 1.57e-02 | 16 |
hsa052109 | Breast | IDC | Colorectal cancer | 17/867 | 86/8465 | 5.70e-03 | 3.13e-02 | 2.34e-02 | 17 |
hsa045109 | Breast | IDC | Focal adhesion | 32/867 | 203/8465 | 8.60e-03 | 4.23e-02 | 3.17e-02 | 32 |
hsa052118 | Breast | IDC | Renal cell carcinoma | 14/867 | 69/8465 | 9.16e-03 | 4.37e-02 | 3.27e-02 | 14 |
hsa0522010 | Breast | IDC | Chronic myeloid leukemia | 15/867 | 76/8465 | 9.24e-03 | 4.37e-02 | 3.27e-02 | 15 |
hsa0471434 | Breast | IDC | Thermogenesis | 75/867 | 232/8465 | 8.41e-21 | 3.04e-19 | 2.27e-19 | 75 |
hsa0520834 | Breast | IDC | Chemical carcinogenesis - reactive oxygen species | 71/867 | 223/8465 | 2.55e-19 | 7.53e-18 | 5.63e-18 | 71 |
hsa0491533 | Breast | IDC | Estrogen signaling pathway | 35/867 | 138/8465 | 2.55e-07 | 5.18e-06 | 3.88e-06 | 35 |
hsa0520533 | Breast | IDC | Proteoglycans in cancer | 42/867 | 205/8465 | 7.69e-06 | 9.99e-05 | 7.48e-05 | 42 |
hsa0516334 | Breast | IDC | Human cytomegalovirus infection | 39/867 | 225/8465 | 6.66e-04 | 5.41e-03 | 4.05e-03 | 39 |
hsa0520332 | Breast | IDC | Viral carcinogenesis | 34/867 | 204/8465 | 2.82e-03 | 1.86e-02 | 1.39e-02 | 34 |
hsa0521413 | Breast | IDC | Glioma | 16/867 | 75/8465 | 3.30e-03 | 2.10e-02 | 1.57e-02 | 16 |
hsa0521014 | Breast | IDC | Colorectal cancer | 17/867 | 86/8465 | 5.70e-03 | 3.13e-02 | 2.34e-02 | 17 |
hsa0451013 | Breast | IDC | Focal adhesion | 32/867 | 203/8465 | 8.60e-03 | 4.23e-02 | 3.17e-02 | 32 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GRB2 | SNV | Missense_Mutation | rs371871562 | c.644G>A | p.Arg215Gln | p.R215Q | P62993 | protein_coding | tolerated(0.25) | benign(0) | TCGA-AO-A0J6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
GRB2 | deletion | Frame_Shift_Del | novel | c.585delN | p.Gly196GlufsTer18 | p.G196Efs*18 | P62993 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
GRB2 | SNV | Missense_Mutation | novel | c.518N>C | p.Gly173Ala | p.G173A | P62993 | protein_coding | tolerated(0.18) | benign(0.164) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
GRB2 | SNV | Missense_Mutation | c.467N>G | p.Gln156Arg | p.Q156R | P62993 | protein_coding | tolerated(0.43) | benign(0.208) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
GRB2 | SNV | Missense_Mutation | c.346N>A | p.Gly116Arg | p.G116R | P62993 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
GRB2 | SNV | Missense_Mutation | novel | c.380N>A | p.Ser127Tyr | p.S127Y | P62993 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
GRB2 | SNV | Missense_Mutation | novel | c.235N>T | p.His79Tyr | p.H79Y | P62993 | protein_coding | tolerated(0.47) | benign(0.003) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
GRB2 | SNV | Missense_Mutation | c.350N>G | p.Lys117Arg | p.K117R | P62993 | protein_coding | tolerated(0.07) | possibly_damaging(0.814) | TCGA-B5-A11H-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Hormone Therapy | megace | SD | |
GRB2 | SNV | Missense_Mutation | rs754676096 | c.173N>G | p.His58Arg | p.H58R | P62993 | protein_coding | tolerated(0.08) | probably_damaging(0.954) | TCGA-B5-A11Y-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GRB2 | SNV | Missense_Mutation | c.238G>A | p.Asp80Asn | p.D80N | P62993 | protein_coding | tolerated(0.5) | benign(0.104) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2885 | GRB2 | NA | LIPOSOMAL GRB-2 | |||
2885 | GRB2 | NA | HEREGULIN | 11175341 | ||
2885 | GRB2 | NA | ACTINOMYCIN D | 15964235 | ||
2885 | GRB2 | NA | ANTINEOPLASTIC | 10403397 | ||
2885 | GRB2 | NA | TCDD | 9918770 |
Page: 1 |